Detecting bolt defects on transmission lines is crucial for ensuring the safe operation of the electrical power system. However, existing methods for detecting bolt defects on transmission lines require higher detection accuracy and smaller model sizes. To address these challenges, this paper proposes a real-time bolt defect detection model based on YOLOv7, named YOLOv7-CWFD. The model integrates the Channel Shuffle Diverse Path Aggregation Network (CSDPAN), significantly reducing computational and parameter complexity while maintaining high detection accuracy. Additionally, weighted Efficient Intersection over Union (EIoU) and Normalized Wasserstein Distance (NWD) loss functions are designed to reduce the network's sensitivity to object size variations and enhance model convergence in regression tasks. The Fast Fourier Channel Attention Mechanism (FFCAM) is introduced between the backbone and neck fusion networks to mitigate excessive smoothing of detailed information and improve the network's sensitivity to objects. The DySample upsampling operator is implemented to replace the upsampling module in the neck fusion network, minimizing information loss during the upsampling process. Experiments conducted on the custom Transmission Line Bolt Defect Dataset (TLBDD) demonstrate a reduction of 10.30MB in model parameter size, along with a 2.30% increase in mean Average Precision (mAP) compared with the original YOLOV7 and a detection speed of 51.15 frames per second (FPS). Experiments on the public dataset CCTSDB further confirm the model's robust generalization capability. These experiments validate the effectiveness of the proposed algorithm.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-024-81386-yDOI Listing

Publication Analysis

Top Keywords

bolt defects
12
defects transmission
12
transmission lines
12
detecting bolt
8
detection accuracy
8
bolt defect
8
network's sensitivity
8
neck fusion
8
detection
5
bolt
5

Similar Publications

Detecting bolt defects on transmission lines is crucial for ensuring the safe operation of the electrical power system. However, existing methods for detecting bolt defects on transmission lines require higher detection accuracy and smaller model sizes. To address these challenges, this paper proposes a real-time bolt defect detection model based on YOLOv7, named YOLOv7-CWFD.

View Article and Find Full Text PDF

Multi-layer conductive structures, especially those with features like bolt holes, are vulnerable to hidden corrosion and cracking, posing a serious threat to equipment integrity. Early defect detection is vital for implementing effective maintenance strategies. However, the subtle signals produced by these defects necessitate highly sensitive non-destructive testing (NDT) techniques.

View Article and Find Full Text PDF

Human DDX49 is an emerging target in cancer progression and retroviral diseases through its essential roles in nucleolar RNA processing. Here, we identify nuclease activity of human DDX49, which requires active site aspartate residues within a conserved region of metazoan DDX49s that is absent from yeast and archaeal DDX49 homologues. We provide evidence that DDX49 nuclease activity is facilitated by its helicase activity.

View Article and Find Full Text PDF

In the literature on rotating machinery, many articles discuss the analysis of various rotor and bearing defects, including both sliding and rolling bearings. Defects in the rotor supporting system are investigated much less frequently. In rotor-bearing-supporting structure systems, where there are couplings between the individual sub-systems, damage to the supporting structure can significantly impact the dynamic properties of the entire machine.

View Article and Find Full Text PDF

Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti-PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a first-in-human, phase 1 study (NCT03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies.

Patients And Methods: Adult patients received 1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks (Q3W) across various dose-escalation schedules.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!